Memphasys (ASX: MEM) has secured CE Mark approval for its Felix System, unlocking immediate commercial opportunities in Europe and activating binding multi-year contracts in Europe and MENA.
CE Mark unlocks European market
The Felix System has achieved CE Mark approval under EU MDR. This critical regulatory milestone grants immediate access to the European market and other CE-recognised regions. It unlocks a near-term addressable market estimated at approximately €29 million per year, or around A$50 million.
Commercial contracts activated
The CE Mark approval activates 2 active binding commercial agreements in Europe and MENA. A 5-year agreement with CFA Italia includes a minimum purchase of 7,500 cartridges, valued at €525,000 (approximately A$925,000). Furthermore, an agreement with ITL MENA secures a minimum purchase value of A$390,000 over 5 years.
Global expansion pathways progressing
Beyond Europe, regulatory pathways for India (CDSCO) and Australia (TGA) are progressing. India CDSCO approval is anticipated in approximately 6 months, with an expected completion date of July 2026. Australia TGA approval is expected by April 2026.
Execution and future outlook
This CE Mark milestone signifies a pivotal transition for Memphasys to commercial execution, with a focus on margin expansion and recurring revenue growth. The company anticipates scaling production and market expansion to drive mid-term upside. Key risks to watch include execution challenges in direct sales, potential manufacturing constraints, and achieving future regulatory milestones in target regions.
Bottom Line
CE Mark approval for the Felix System is a critical step for Memphasys, enabling immediate European commercial rollout and activating secured contracts. The company is now positioned to leverage this milestone for further market expansion, though successful execution and continued regulatory progress remain key.
